Evidence map›Paper›PMID 11420707›Full record

ArticleOncogene2001

Loss of p53 tumor suppressor function is required for in vivo progression of Friend erythroleukemia.

J M Prasher, K S Elenitoba-Johnson, L L Kelley

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.3field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. The impact of p53 loss on murine plasmacytoma development.Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology · 2002
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

J M PrasherDepartment of Pathology, University of Utah School of Medicine and the Huntsman Cancer Institute, Salt Lake City, Utah, UT 84132, USA.
K S Elenitoba-Johnson
L L Kelley
Huntsman Cancer Institute · USUniversity of Utah · US

Funding

EXPRESSION PROFILING OF PROGRESSED FOLLICULAR LYMPHOMASR21CA083984 · NCI · UNIVERSITY OF UTAH · PI ELENITOBA-JOHNSON, KOJO SEYS · 2000 to 2001
$225k
ROLE OF BETA-2 INTEGRINS IN LEUKOCYTE ADHESION AND SIGNALINGP50DK049219 · NIDDK · UNIVERSITY OF UTAH · PI SPANGRUDE, GERALD J · 1994 to 2000
$75k
NCI NIH HHS CA83984-01NIDDK NIH HHS P50DK49219
6 · The paper itself

Abstract

A role for p53 in the in vivo progression of Friend virus-induced erythroleukemia has been suggested but not clearly defined. We developed a Friend virus-sensitive, p53-deficient mouse model to directly address the role of p53 in Friend erythroleukemia. When infected with the polycythemia-inducing strain of Friend virus (FVP), p53 null mice exhibited accelerated progression to erythroleukemia and accelerated death following diagnosis when compared to wild type mice. Confirmation that p53 mutations were required for disease progression was provided by sequence analysis of p53 transcripts in leukemic wild type and heterozygous mice. All transcripts evaluated had point mutations, deletions or insertions in the p53 gene. The ability to grow tumor colonies in vitro and derive cell lines was enhanced in FVP-infected p53 null animals. Although PU.1 oncogene overexpression is a common mutation observed in cell lines derived from Friend virus-infected p53 wild type mice, it was not a universal finding in cell lines derived from p53 null animals. Our data conclusively demonstrate that loss of p53 function is a requirement for progression of Friend erythroleukemia in vivo. Further, the data demonstrate that erythroleukemias arising in Friend virus-infected p53 null mice are biologically and genetically distinct from those that occur in wild type animals, suggesting that the temporal order of PU.1 and p53 mutations is an important parameter in the pathogenesis of leukemic development.

Indexed as

Genes, Tumor SuppressorAnimalsDNA-Binding ProteinsFemaleFriend murine leukemia virusInterferon Regulatory Factor-4Interferon Regulatory FactorsLeukemia, Erythroblastic, AcuteMiceMice, Mutant StrainsMutationSurvival RateTrans-ActivatorsTumor Cells, CulturedTumor Stem Cell AssayTumor Suppressor Protein p53DNA-Binding ProteinsInterferon Regulatory Factor-4Interferon Regulatory FactorsTrans-ActivatorsTumor Suppressor Protein p53

Identifiers

PMID11420707
OpenAlexW2319948084

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.